TAURIGA SCIENCES INC - TAUG STOCK NEWS

Tauriga Sciences, Inc. (OTCQB: TAUG) has announced a doubled production run for its Delta 8 THC-infused Tauri-Gum™ due to strong demand and pre-orders. The company reported record monthly sales for April 2021, surpassing its previous record of approximately $47,000. Factors driving this growth include strong E-Commerce performance and pre-orders for both the Delta 8 THC and enhanced 25mg CBD/CBG versions of Tauri-Gum™. Additionally, Tauriga continues its pharmaceutical development initiative for a cannabinoid-based anti-nausea chewing gum for chemotherapy patients.

Tauriga Sciences, Inc. (OTCQB: TAUG) announced the launch of its new product line, the Tauri-Gum™ Summertime Collection, which includes an embroidered Hiking Backpack ($149.99), Folding Beach Chair ($64.99), and Insulated Can Cooler ($8.99 each). Set to be available on their E-Commerce site starting May 2021, the collection aims to promote outdoor activities. Tauriga specializes in CBD and CBG infused products and is involved in a Pharmaceutical Development initiative for a medicinal version of their Tauri-Gum™ for nausea regulation during chemotherapy.

Tauriga Sciences, Inc. (OTCQB: TAUG) announced the launch of its new Delta 8 THC infused Tauri-Gum™, with the Evergreen Mint flavor priced at $18.99 per blister pack. The company is also participating in a large-scale human safety study conducted by Validcare, including its cannabinoid-based anti-nausea gum in the approved cohort. This initiative aims to gather data for FDA approval. Tauriga continues to advance its proprietary CBD and CBG product lines while focusing on pharmaceutical development, especially for patients undergoing chemotherapy.

Tauriga Sciences, Inc. (TAUG) announces significant pre-orders for its new 25mg CBD & CBG infused Tauri-Gum™ products, including flavors like Mint and Blood Orange. The company has successfully reduced production costs, ensuring no increase in retail prices. Strong e-commerce sales in the first half of April 2021 bolster confidence in growth prospects for FY 2022. Additionally, Tauriga is advancing its pharmaceutical initiative for a nausea-regulation product aimed at chemotherapy patients, highlighted by a recent patent application conversion.

Tauriga Sciences, Inc. (OTCQB: TAUG) has announced the formation of a new division named NFTauriga Corp., aimed at creating and marketing Non-Fungible Tokens (NFTs) as part of its long-term branding strategies. The division will produce unique digital assets while retaining full ownership rights. The company highlights the potential for NFTs to enhance web traffic, revenue, and social cause support. Tauriga's existing product lines include CBD and CBG infused chewing gums, with ongoing pharmaceutical development initiatives. Shareholders will receive updates on NFT progress.

Tauriga Sciences (OTCQB: TAUG) is set to present at the SEQUIRE 2021 Cannabis Conference on April 20, 2021, from 1:00 pm to 1:25 pm EST. The company specializes in CBD and CBG-infused chewing gums under the Tauri-Gum™ brand, offering various flavors, including Pomegranate and Mint. CEO Seth M. Shaw will lead the presentation to more than 3 million investors on the SEQUIRE platform. Additionally, Tauriga is advancing a pharmaceutical-grade Tauri-Gum™ for nausea regulation in chemotherapy patients and has recently converted its provisional patent into a non-provisional application.

Tauriga Sciences, Inc. (TAUG) announced record daily results in their E-Commerce business, achieving over $10,000 in sales on April 5, 2021, with 207 transactions. As of the following morning, approximately 5,900 E-Commerce orders were received. Additionally, the company has completed payment for the initial production of a Delta-8-THC infused Tauri-Gum, set to retail at $18.99 per pack. Tauriga focuses on CBD and CBG-infused products, with a robust online presence and two fulfillment centers.

Tauriga Sciences, Inc. (TAUG) has completed its translated packaging for Tauri-Gum™, enhancing its international expansion efforts. The new packaging supports twelve languages including Mandarin, Arabic, and Spanish, aimed at broadening its CBD and CBG infused product market. The Tauri-Gum™ line has increased the infusion concentration to 25mg. Additionally, the company is advancing its pharmaceutical development for a CBD-based product designed to assist chemotherapy patients, having filed a non-provisional patent application.

Tauriga Sciences, Inc. (OTCQB: TAUG) announced its registration on BidNet Direct, allowing it to bid on U.S. Government contracts. As a verified federal vendor (CAGE CODE # 8QXV4), the Company aims to diversify its revenue streams further. Tauriga offers a line of CBD and CBG infused chewing gums and is also involved in ongoing pharmaceutical development. The Company converted a U.S. Provisional Patent Application into a Non-Provisional Patent Application for a medicated version of its Tauri-Gum™ targeted at chemotherapy patients.